The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials

BACKGROUND AND PURPOSE: Although bevacizumab (BV) has been approved as second-line therapy for recurrent glioblastoma (GB), the efficacy and safety of BV for patients with newly diagnosed GB remain unclear. METHODOLOGY/PRINCIPAL FINDINGS: We systematically searched electronic databases (PubMed, EMBA...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yuping, Hou, Mengzhuo, Lu, Guangyu, Ciccone, Natalia, Wang, Xingdong, Zhang, Hengzhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179058/
https://www.ncbi.nlm.nih.gov/pubmed/28005980
http://dx.doi.org/10.1371/journal.pone.0168264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179058/
https://www.ncbi.nlm.nih.gov/pubmed/28005980
http://dx.doi.org/10.1371/journal.pone.0168264

Ejemplares similares